Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer

作者：You Lü, Jianxin Xue, Tao Deng, Xiaojuan Zhou, Kun Yu, Lei Deng, Meijuan Huang, Xin Yi, Maozhi Liang, Yu Wang, Haige Shen, Ruizhan Tong, Wenbo Wang, Li Li, Jin Sook Song, Jing Li, Xiaoxing Su, Zhenyu Ding, Youling Gong, Jiang Zhu, Yongsheng Wang, Bingwen Zou, Yan Zhang, Yanying Li, Lin Zhou, Yongmei Liu, Min Yu, Yuqi Wang, Xuanwei Zhang, Limei Yin, Xuefeng Xia, Yong Zeng, Qiao Zhou, Binwu Ying, Chong Chen, Yuquan Wei, Weimin Li, Tony Mok · 发表于：Nature Medicine · 年份：2020 · DOI：10.1038/s41591-020-0840-5 · 被引用次数：545 · 研究领域：CRISPR and Genetic Engineering、CAR-T cell therapy research、Virus-based gene therapy research